Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sara Dorado
Observed name:
S. Dorado
Institution:
Universidad Carlos III de Madrid
Observed institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre,
Universidad Carlos III de Madrid
ORCID:
0000-0002-4144-0315
Observed ORCID:
0000-0002-4144-0315
OpenAlex ID:
A5045738997
Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT
2023
·
Ana Jiménez-Ubieto
, María Poza
, et al.
·
Leukemia
·
48
PDF
Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence
2024
·
J. Martinez-Lopez
, N. Lopez-Muñoz
, et al.
·
Blood Cancer Journal
·
22
PDF
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
2022
·
Ricardo Sánchez
, Sara Dorado
, et al.
·
Scientific Reports
·
16
PDF
Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges
2024
·
Noemí Álvarez
, Alejandro Martín
, et al.
·
Frontiers in Immunology
·
14
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
2023
·
Ana Jiménez-Ubieto
, Alejandro Martín-Muñoz
, et al.
·
Frontiers in Immunology
·
12
Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma
2023
·
Seungbin Han
, Umair Munawar
, et al.
·
Blood
·
9
Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH
2021
·
Ana Jimenez-Ubieto
, María Poza
, et al.
·
Blood
·
4
A Supervised Machine Learning Model to Predict Therapy Response and Mortality at 90 days After Acute Myeloid Leukemia Diagnosis
2023
·
Juan A. Delgado Sanchis
, Pedro Pons-Suñer
, et al.
·
medRxiv
·
3
PDF
Identification of relevant features using SEQENS to improve supervised machine learning models predicting AML treatment outcome
2025
·
Pedro Pons-Suñer
, François Signol
, et al.
·
BMC Medical Informatics and Decision Making
·
2
PDF
Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
2024
·
Ricardo Sánchez
, Sara Dorado
, et al.
·
Scientific Reports
·
1
PDF
Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant
2023
·
Irene Zamanillo
, Santiago Barrio
, et al.
·
Blood
·
1
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
2023
·
Ana Jiménez-Ubieto
, Alejandro Martín-Muñoz
, et al.
·
Frontiers in Immunology
·
1
PDF
Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
2022
·
Alejandro Martín-Muñoz
, María Poza
, et al.
·
Blood
·
1
Deep Diffusion Autoencoders
2019
·
Sara Dorado
, Angela Fernandez
, et al.
·
International Joint Conference on Neural Networks (IJCNN)
·
1
PDF
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
2024
·
Ana Jiménez-Ubieto
, Alejandro Martín-Muñoz
, et al.
·
Frontiers in Immunology
PDF
Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma
2023
·
Santiago Barrio
, Carolina Martinez-Laperche
, et al.
·
Blood
P702: Application of Next Generation Sequencing (ngs) for Minimal Residual Disease (mrd) and Chimerism Monitoring in Myelodysplastic Syndrome (mds) After Allogenic Stem Cell Transplantation (asct)
2023
·
Irene Zamanillo
, Santiago Barrio
, et al.
·
HemaSphere
P1100: Pet Interim Results Could Promptly Select Follicular Lymphoma Patients in Need of Maintenance Therapy. Potential Additional Value of Cfdna.
2023
·
Maria Poza
, Patricia López-Pereira
, et al.
·
HemaSphere
Pb1781: the Application of Cf-dna for Ngs Mrd Studies in Patients With Lma Improves the Sensitivity of the Method With Respect to Ctc.
2023
·
Noemí Álvarez Sánchez-Redondo
, Alejandro Martin
, et al.
·
HemaSphere
Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring.
2023
·
Joaquin Martinez-Lopez
, Sandy Wai Kuan Wong
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
20
Citation count:
135
H-index:
6
I10-index:
5
Year
Topic
Type